Share This Article:

Adjuvant Taxanes in Breast Cancer: A Critical Re-appraisal

Abstract Full-Text HTML Download Download as PDF (Size:81KB) PP. 317-321
DOI: 10.4236/jct.2011.23043    5,659 Downloads   9,796 Views  

ABSTRACT

Purpose: Several studies have reported a positive impact for taxanes in adjuvant breast cancer (BC) treatment in terms of reduced recurrence and mortality. However the impact of the magnitude on overall survival (OS) remains partially controversial. Methods: We examined the impact of taxane-containing adjuvant therapy for patients with early BC on OS, based on the number of deaths and on the calculated number of patients who need to be treated with taxanes to avoid one death (NNT). We classified patients in three different groups according to whether taxanes were administered concurrently or sequentially, and whether all treatment arms had the same or different duration. Results: 1) Taxanes in combination therapy: 8258 patients (4373 with taxanes and 3885 without taxanes), with 723 OS events. Overall survival for taxane-treated patients was 92.7% versus 89.6% for patients not receiving taxanes. NNT was 33. 2) Sequential treatment of unequal duration in the treatment arms: 14,228 patients (7970 with taxanes and 6256 without). Overall survival in taxane-treated patients was 86% compared with 83.2% for patients not receiving taxanes. NNT was 44. 3) Sequential treatment and similar duration in treatment arms: 9511 women (5093 with taxanes and 4418 without). Overall survival in patients treated with taxanes was 87% versus 85% in patients not receiving taxanes. NNT was 50. When the results of all these trials were considered together, the NNT stands at 43 patients. Conclusion: Taxanes afford a modest increase in overall survival in BC patients regardless of how they are given. Translational trials may well help to improve patient selection in the future.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Sánchez-Muñoz, N. Ribelles and E. Alba, "Adjuvant Taxanes in Breast Cancer: A Critical Re-appraisal," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 317-321. doi: 10.4236/jct.2011.23043.

References

[1] T. Ferguson, N. Wilcken, R. Vagg, D. Ghersi and A. K. Nowak, “Taxanes for Adjuvant Treatment of Early Breast Cancer,” Cochrane Review, Vol. 17, No. 4, 2007, p. 4421. doi:10.1002/14651858.
[2] M. De Laurentiis, G. Arpino and E. Massarelli, et al., “A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer,” Clinical Cancer Research, Vol. 17, No. 15, 2005, pp. 4741-4748. doi:10.1158/1078-0432.CCR-04-2569
[3] M. Martin, T. Pienkowski and J. Mackey, et al., “Adjuvant Docetaxel for Node-Positive Breast Cancer,” The New England Journal of Medicine, Vol. 352, 2005, pp. 2302-2313. doi:10.1056/NEJMoa043681
[4] P. Francis, J. Crown, A. Di Leo and M. Buyse, et al., “Adjuvant Chemotherapy with Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial,” Journal of the National Cancer Institution, Vol. 100, No. 2, 2008, pp. 121-133. doi:10.1093/jnci/djm287
[5] M. Martin, A. Lluch and M. A. Segui, et al., “TAC versus FAC as Adjuvant Chemotherapy for High-Risk Node-Negative Breast Cancer: Results of the GEICAM 9805 Trial,” Annual Oncology, Vol. 19, 2008, p. 1830.
[6] S. Jones, F. A. Holmes and J. O’Shaughnessy, “Docetaxel with Cyclophosphamide Is Associated with an Overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-up of US Oncology Research Trial 9735,” Journal of Clinical Oncology, Vol. 27, No. 8, 2009, pp. 1177-1183. doi:10.1200/JCO.2008.18.4028
[7] I. C. Henderson, D. A. Berry and G. D. Demetri, “Improved Outcomes from Adding Sequential Paclitaxel but not from Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients with Node-Positive Primary Breast Cancer,” Journal of Clinical Oncology, Vol. 21, No. 6, 2003, pp. 976-983. doi:10.1200/JCO.2003.02.063
[8] E. P. Mamounas, J. Bryant and B. Lembersky, “Paclitaxel after Doxorubicin plus Cyclophosphamide as Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results from NSABP B-28,” Journal of Clinical Oncology, Vol. 23, No. 16, 2005, pp. 3686-3696. doi:10.1200/JCO.2005.10.517
[9] L. Gianni, J. Baselga and W. Eiermann, et al., “Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, as Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer,” Journal of Clinical Oncology, Vol. 27, No. 15, 2009, pp. 2474-2481. doi:10.1200/JCO.2008.19.2567
[10] A. Polyzos, N. Malamos and I. Boukovinas, et al., “FEC versus Sequential Docetaxel Followed by Epirubicin/ Cyclophosphamide as Adjuvant Chemotherapy in Women with Axillary Node-Positive Early Breast Cancer: A Randomized Study of the Hellenic Oncology Research Group (HORG),” Breast Cancer Research and Treatment, Vol. 119, No. 1, 2010, pp. 95-104. doi:10.1007/s10549-009-0468-0
[11] H. Roche, P. Fumoleau and M. Spielmann, “Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial,” Journal of Clinical Oncology, Vol. 24, No. 36, 2006, pp. 5664-5671. doi:10.1200/JCO.2006.07.3916
[12] M. Martin, A. Rodriguez-Lescure and A. Ruiz, “Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer,” Journal of the National Cancer Institution, Vol. 100, No. 11, 2008, pp. 805-814. doi:10.1093/jnci/djn151
[13] T. R. Evans, A. Yellowlees and E. Foster, et al., “Phase III Randomized Trial of Doxorubicin and Docetaxel versus Doxorubicin and Cyclophosphamide as Primary Medical Therapy in Women with Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study,” Journal of Clinical Oncology, Vol. 23, No. 13, 2005, pp. 2988-2895. doi:10.1200/JCO.2005.06.156
[14] L. J. Goldstein, A. O’Neill and J. A. Sparano, et al., “Concurrent Doxorubicin Plus Docetaxel is not More Effective than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer with 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197,” Journal of Clinical Oncology, Vol. 26, No. 25, 2008, pp. 4092-4099. doi:10.1200/JCO.2008.16.7841
[15] A. U. Buzdar, S. E. Singletary and V. Valero, et al., “Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial,” Clinical Cancer Research, Vol. 8, 2002, pp. 1073-1079.
[16] G. Fountzilas, D. Skarlos and U. Dafni, “Postoperative Dose-Dense Sequential Chemotherapy with Epirubicin, Followed by CMF with or without Paclitaxel, in Patients with High-Risk Operable Breast Cancer: A Randomized Phase III Study Conducted by the Hellenic Cooperative Oncology Group,” Annals of Oncology, Vol. 16, No. 11, 2005, pp. 1762-1771. doi:10.1093/annonc/mdi366
[17] H. D. Bear, S. Anderson and R. E. Smith, et al., “Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27,” Journal of Clinical Oncology, Vol. 24, No. 13, 2006, pp. 2019-2027. doi:10.1200/JCO.2005.04.1665
[18] A. R. Bianco, A. De Matteis and L. Manzione, “Sequential Epirubicin-Docetaxel-CMF as Adjuvant Therapy of Early Breast Cancer: Results of the Taxit216 Multicenter Phase III Trial,” Journal of Clinical Oncology, Vol. 24, No. 18, 2006, p. 520.
[19] M. J. Burnell, M. N. Levine and J. A. Chapman, et al., “Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer,” Journal of Clinical Oncology, Vol. 28, No. 1, 2010, pp. 77-82. doi:10.1200/JCO.2009.22.1077
[20] P. Ellis, P. Barrett-Lee and L. Johnson, et al., “Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT): An Open-Label, Phase III, Randomised Controlled Trial,” Lancet, Vol. 373, 2009, pp. 1681-1692. doi:10.1016/S0140-6736(09)60740-6
[21] D. A. Berry, C. Cirrincione and I. G. Henderson, et al., “Estrogen Receptor Status and Outcomes of Modern Chemotherapy for Patients with Node-Positive Breast Cancer,” The Journal of the American Medical Association, Vol. 295, No. 14, 2006, pp. 1658-1667. doi:10.1001/jama.295.14.1658
[22] D. F. Hayes, A. D. Thor and L. G. Dressler, et al., “Her2 and Response to Paclitaxel in Node Positive Breast Cancer,” The New England Journal of Medicine, Vol. 357, 2007, pp. 1496-1506. doi.org/10.1056/NEJMoa071167

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.